ユーザーIDをお忘れですか? or パスワードをお忘れですか?

東京ビッグサイト | 有明

2018年11月11日 (日) 午前 9:30 - 2018年11月13日 (火) 午後 5:40

〒135-0063, 東京都江東区有明3-11-1



[V7-S3] Various Initiatives after Marketing of Regenerative Medical Products

Session Chair(s)

Yoji  Sato, PhD

Yoji Sato, PhD

Head, Division of Drugs

National Institute of Health Sciences, Japan

Currently 4 products are approved for regenerative medicine and other products, moreover, efforts are underway for various research and business development. In this session, we need to understand the outline of the National Consortium established by the Society of Regenerative Medicine, explain the status of support at the academic society and the data registration system and the patient registration system. We discuss the future issues and expectations by asking their opinions from each point of view on issues and expected outcome from databases and ongoing operations.


Kazuhisa  Koike, PhD

Safety Measures for Regenerative Medical Products in PMS

Kazuhisa Koike, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Office of Medical Devices

Mariko  Okada, DVM

Collaboration with Academia for Patient Registration System from Industry Standpoint

Mariko Okada, DVM

JCR Pharmaceutical Co., Ltd., Japan

Director, PV

Kiyoshi  Okada, MD, PhD

Outline of Regenerative Medical National Consortium

Kiyoshi Okada, MD, PhD

Osaka University Hospital, Japan

Vice Director, Medical Ctr for Translational Research,Dept of Medical Innovation